Sorriso Pharmaceuticals Launches with $31 Million to Develop Novel Class of Orally Delivered Cytokine Antibodies to Treat Inflammatory Conditions
Series A Financing Funds Multiple Programs to Phase 1 and IND stage […]
Series A Financing Funds Multiple Programs to Phase 1 and IND stage […]
Definitive merger agreements provide the Company with all existing and future assets, future product iterations, and intellectual property rights of the platform, creating a fully integrated product line and streamlining commercialization […]
Publication in Journal of the American College of Cardiology (JACC): Cardiovascular Interventions Found TRIA Aortic Heart Valve Provided Sustained Improvement in Heart Valve Function to One-Year with Good Safety Profile […]
PolarityTE has submitted its complete response to the U.S. FDA clinical hold correspondence regarding its Investigational New Drug (IND) Application for SkinTE® with a proposed indication for chronic cutaneous ulcers. […]
Myriad Genetics Promotes Nicole Lambert to Chief Operating Officer […]
Teiko.bio Launches with $11.6 Million Series A Financing to Advance High-Dimension Immune Profiling for Clinical Trials and Diagnostics Development. […]
Rosivo closes seed-round paving the path for commercialization of patented cartilage implant technology […]
Pfizer and Arena Pharmaceutical on Dec. 13 announced that the companies have entered into an agreement under which Pfizer will acquire Arena, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases. Under the terms of the agreement, Pfizer will acquire all the outstanding shares of Arena for $100 per […]
IONIQ Sciences, Inc. announced it has been awarded “Most Innovative Non-Invasive Lung Cancer Testing Solution” and “Best Medical Technology Company 2021” by Global 100. […]
Powerful combination of key patents comes as the Company looks ahead to topline results from a Phase 3 registration study in ALS in second half of 2022. […]
Clene presented data from the RESCUE-ALS Phase 2 study of CNM-Au8®, a catalytically active gold nanocrystal suspension, for the treatment of amyotrophic lateral sclerosis (ALS). […]
Arena Pharmaceuticals, Inc. and Pfizer Inc. have entered into a definitive agreement under which Pfizer will acquire Arena. […]